Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1

Interventions

Carboplatin 6Pemetrexed 5pembrolizumab 3selpercatinib 2pralsetinib 2osimertinib 2durvalumab 2camrelizumab 2Cisplatin 2taletrectinib 1repotrectinib 1motexafin gadolinium 1exemestane 1entinostat 1ceralasertib 1belinostat 1belagenpumatucel L 1alectinib 1TNFSF10 protein, human 1Patient Reported Outcome Measures 1Paclitaxel 1Oncolytic Virotherapy 1Injections 1Gemcitabine 1Fluorouracil 1Erlotinib Hydrochloride 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Bronchogenic × belagenpumatucel L × Clear all
NCT01058785 2010-07-29

Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer

NovaRx Corporation

Phase 2 Completed
75 enrolled
Thoracic

Carcinoma, Bronchogenic, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡